Aegis Life Announces Start of Phase 1/2 Trial of the Entos COVID-19 DNA Vaccine, Covigenix VAX-001, with First Participants Dosed

AEGIS LIFE ANNOUNCES START OF PHASE 1/2 TRIAL OF THE ENTOS COVID-19 DNA VACCINE, COVIGENIX VAX-001, WITH FIRST PARTICIPANTS DOSED Published by: Aegis Life Business Wire News Release April 16, 2021 12:26 PM Eastern Daylight Time SAN DIEGO–(BUSINESS WIRE)–Aegis Life, Inc. announced today that the first participants

Read more

Entos Working with Applied Pharmaceutical Innovation to Enable in-house Development and Manufacturing Capability of COVID-19 DNA Vaccine

ENTOS WORKING WITH APPLIED PHARMACEUTICAL INNOVATION TO ENABLE IN-HOUSE DEVELOPMENT AND MANUFACTURING CAPABILITY OF COVID-19 DNA VACCINE Published by: Aegis Life Entos is working with Applied Pharmaceutical Innovation (API) to ensure secure supply of inputs for its vaccine production and the ability to expand its Edmonton facilities.

Read more

Entos Announces Launch of US Spinout Aegis Life to Support its Global Vaccine Strategy & Signs License Agreement with NTC

ENTOS ANNOUNCES LAUNCH OF US-BASED SPINOUT COMPANY AEGIS LIFE TO SUPPORT ITS GLOBAL VACCINE COMMERCIALIZATION STRATEGY AND SIGNS LICENSE AGREEMENT WITH NTC TO USE NANOSPLASMID VECTOR TECHNOLOGY IN VACCINES Published by: Aegis Life EDMONTON, AB, October 15, 2020 – Entos Pharmaceuticals (Entos), a Canadian biotechnology company developing

Read more

Entos Announces Selection of Lead DNA Vaccine Candidates for COVID-19 and a $4.2M Award to Move Forward with Phase I/II Human Trials

ENTOS ANNOUNCES SELECTION OF LEAD DNA VACCINE CANDIDATES FOR COVID-19 AND A $4.2M AWARD TO MOVE FORWARD WITH PHASE I/II HUMAN TRIALS Published by: Aegis Life EDMONTON, AB, June 25, 2020 – Entos Pharmaceuticals (Entos), a healthcare biotechnology company developing nucleic acid medicines with its Fusogenix drug delivery platform,

Read more

Entos Partners with Precision NanoSystems to Enable Scalable GMP Manufacturing of Fusogenix COVID-19 Vaccine

ENTOS PHARMACEUTICALS PARTNERS WITH PRECISION NANOSYSTEMS TO ENABLE HIGHLY SCALABLE GMP MANUFACTURING OF FUSOGENIX DNA COVID-19 VACCINE Published by: Aegis Life   EDMONTON, Alberta, May 7, 2020 — Entos Pharmaceuticals (Entos), a healthcare biotechnology company developing next generation nucleic acid medicines with their Fusogenix delivery platform announced

Read more